Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 409 to 416 of 416 entries
Sorted by: Best Match Show Resources per page
Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.

Bioorganic & medicinal chemistry

Xu S, Song S, Sun L, Gao P, Gao S, Ma Y, Kang D, Cheng Y, Zhang X, Cherukupalli S, De Clercq E, Pannecouque C, Liu X, Zhan P.
PMID: 34890994
Bioorg Med Chem. 2022 Jan 01;53:116531. doi: 10.1016/j.bmc.2021.116531. Epub 2021 Dec 03.

To explore the chemical space around the entrance channel of the HIV-1 reverse transcriptase (RT) binding pocket, we innovatively designed and synthesized a series of novel indolylarylsulfones (IASs) bearing phenylboronic acid and phenylboronate ester functionalities at the indole-2-carboxamide as...

Cite
Xu S, Song S, Sun L, et al. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 2021;53:116531doi: 10.1016/j.bmc.2021.116531.
Xu, S., Song, S., Sun, L., Gao, P., Gao, S., Ma, Y., Kang, D., Cheng, Y., Zhang, X., Cherukupalli, S., De Clercq, E., Pannecouque, C., Liu, X., & Zhan, P. (2022). Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors. Bioorganic & medicinal chemistry, 53116531. https://doi.org/10.1016/j.bmc.2021.116531
Xu, Shujing, et al. "Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors." Bioorganic & medicinal chemistry vol. 53 (2022): 116531. doi: https://doi.org/10.1016/j.bmc.2021.116531
Xu S, Song S, Sun L, Gao P, Gao S, Ma Y, Kang D, Cheng Y, Zhang X, Cherukupalli S, De Clercq E, Pannecouque C, Liu X, Zhan P. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 2022 Jan 01;53:116531. doi: 10.1016/j.bmc.2021.116531. Epub 2021 Dec 03. PMID: 34890994.
Copy Download .nbib Format: NLM
A Combined approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and in silico ADME/Tox prediction of 4-Arylthio & 4- Aryloxy-3- Iodopyridine-2(1H)-one analogs to identify potential Reverse Transcriptase inhibitor: Anti-HIV agents.

Medicinal chemistry (Shariqah (United Arab Emirates))

Panigrahi D, Mishra A, Sahu SK, Azam MA, Vyshaag CM.
PMID: 33319692
Med Chem. 2020 Dec 13; doi: 10.2174/1573406417666201214100822. Epub 2020 Dec 13.

BACKGROUND: Reverse transcriptase is an important therapeutic target to treat AIDS caused by the Human Immunodeficiency Virus (HIV). Despite many effective anti-HIV drugs, reverse transcriptase (RT) inhibitors remain the cornerstone of the drug regimen to treat AIDS. In the...

Cite
Panigrahi D, Mishra A, Sahu SK, et al. A Combined approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and in silico ADME/Tox prediction of 4-Arylthio & 4- Aryloxy-3- Iodopyridine-2(1H)-one analogs to identify potential Reverse Transcriptase inhibitor: Anti-HIV agents. Med Chem. 2020;doi: 10.2174/1573406417666201214100822.
Panigrahi, D., Mishra, A., Sahu, S. K., Azam, M. A., & Vyshaag, C. M. (2020). A Combined approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and in silico ADME/Tox prediction of 4-Arylthio & 4- Aryloxy-3- Iodopyridine-2(1H)-one analogs to identify potential Reverse Transcriptase inhibitor: Anti-HIV agents. Medicinal chemistry (Shariqah (United Arab Emirates)), . https://doi.org/10.2174/1573406417666201214100822
Panigrahi, Debadash, et al. "A Combined approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and in silico ADME/Tox prediction of 4-Arylthio & 4- Aryloxy-3- Iodopyridine-2(1H)-one analogs to identify potential Reverse Transcriptase inhibitor: Anti-HIV agents." Medicinal chemistry (Shariqah (United Arab Emirates)) vol. (2020). doi: https://doi.org/10.2174/1573406417666201214100822
Panigrahi D, Mishra A, Sahu SK, Azam MA, Vyshaag CM. A Combined approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and in silico ADME/Tox prediction of 4-Arylthio & 4- Aryloxy-3- Iodopyridine-2(1H)-one analogs to identify potential Reverse Transcriptase inhibitor: Anti-HIV agents. Med Chem. 2020 Dec 13; doi: 10.2174/1573406417666201214100822. Epub 2020 Dec 13. PMID: 33319692.
Copy Download .nbib Format: NLM
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.

Antimicrobial agents and chemotherapy

Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R.
PMID: 34694877
Antimicrob Agents Chemother. 2021 Oct 25;AAC0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25.

At Week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy....

Cite
Underwood M, Horton J, Nangle K, et al. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. Antimicrob Agents Chemother. 2021;AAC0164321doi: 10.1128/AAC.01643-21.
Underwood, M., Horton, J., Nangle, K., Hopking, J., Smith, K., Aboud, M., Wynne, B., Sievers, J., Stewart, E. L., & Wang, R. (2021). Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. Antimicrobial agents and chemotherapy, AAC0164321. https://doi.org/10.1128/AAC.01643-21
Underwood, Mark, et al. "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study." Antimicrobial agents and chemotherapy vol. (2021): AAC0164321. doi: https://doi.org/10.1128/AAC.01643-21
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. Antimicrob Agents Chemother. 2021 Oct 25;AAC0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25. PMID: 34694877.
Copy Download .nbib Format: NLM
Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction.

Current opinion in HIV and AIDS

Côté HC.
PMID: 19372896
Curr Opin HIV AIDS. 2007 Jul;2(4):253-60. doi: 10.1097/COH.0b013e3281df3410.

PURPOSE OF REVIEW: To discuss novel developments related to the mechanisms of antiretroviral therapy-related mitochondrial toxicity, describe some apparent paradoxes in the current understanding of this field, and present questions that should be addressed by future research.RECENT FINDINGS: The...

Cite
Côté HC. Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction. Curr Opin HIV AIDS. 2007;2(4):253-60doi: 10.1097/COH.0b013e3281df3410.
Côté, H. C. (2007). Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction. Current opinion in HIV and AIDS, 2(4), 253-60. https://doi.org/10.1097/COH.0b013e3281df3410
Côté, Hélène C F. "Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction." Current opinion in HIV and AIDS vol. 2,4 (2007): 253-60. doi: https://doi.org/10.1097/COH.0b013e3281df3410
Côté HC. Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction. Curr Opin HIV AIDS. 2007 Jul;2(4):253-60. doi: 10.1097/COH.0b013e3281df3410. PMID: 19372896.
Copy Download .nbib Format: NLM
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.

Journal of the International AIDS Society

Phongsamart W, Jantarabenjakul W, Chantaratin S, Anugulruengkitt S, Suntarattiwong P, Sirikutt P, Kosalaraksa P, Maleesatharn A, Chokephaibulkit K.
PMID: 35001501
J Int AIDS Soc. 2022 Jan;25(1):e25862. doi: 10.1002/jia2.25862.

INTRODUCTION: Efavirenz (EFV) is commonly used for first-line antiretroviral therapy in children and adolescents with HIV, but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV in virologically suppressed...

Cite
Phongsamart W, Jantarabenjakul W, Chantaratin S, et al. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. J Int AIDS Soc. 2022;25(1):e25862doi: 10.1002/jia2.25862.
Phongsamart, W., Jantarabenjakul, W., Chantaratin, S., Anugulruengkitt, S., Suntarattiwong, P., Sirikutt, P., Kosalaraksa, P., Maleesatharn, A., & Chokephaibulkit, K. (2022). Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. Journal of the International AIDS Society, 25(1), e25862. https://doi.org/10.1002/jia2.25862
Phongsamart, Wanatpreeya, et al. "Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand." Journal of the International AIDS Society vol. 25,1 (2022): e25862. doi: https://doi.org/10.1002/jia2.25862
Phongsamart W, Jantarabenjakul W, Chantaratin S, Anugulruengkitt S, Suntarattiwong P, Sirikutt P, Kosalaraksa P, Maleesatharn A, Chokephaibulkit K. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. J Int AIDS Soc. 2022 Jan;25(1):e25862. doi: 10.1002/jia2.25862. PMID: 35001501; PMCID: PMC8743364.
Copy Download .nbib Format: NLM
Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.

Bioorganic & medicinal chemistry

Xu S, Song S, Sun L, Gao P, Gao S, Ma Y, Kang D, Cheng Y, Zhang X, Cherukupalli S, De Clercq E, Pannecouque C, Liu X, Zhan P.
PMID: 34890994
Bioorg Med Chem. 2021 Dec 03;53:116531. doi: 10.1016/j.bmc.2021.116531. Epub 2021 Dec 03.

To explore the chemical space around the entrance channel of the HIV-1 reverse transcriptase (RT) binding pocket, we innovatively designed and synthesized a series of novel indolylarylsulfones (IASs) bearing phenylboronic acid and phenylboronate ester functionalities at the indole-2-carboxamide as...

Cite
Xu S, Song S, Sun L, et al. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 2021;53:116531doi: 10.1016/j.bmc.2021.116531.
Xu, S., Song, S., Sun, L., Gao, P., Gao, S., Ma, Y., Kang, D., Cheng, Y., Zhang, X., Cherukupalli, S., De Clercq, E., Pannecouque, C., Liu, X., & Zhan, P. (2021). Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors. Bioorganic & medicinal chemistry, 53116531. https://doi.org/10.1016/j.bmc.2021.116531
Xu, Shujing, et al. "Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors." Bioorganic & medicinal chemistry vol. 53 (2021): 116531. doi: https://doi.org/10.1016/j.bmc.2021.116531
Xu S, Song S, Sun L, Gao P, Gao S, Ma Y, Kang D, Cheng Y, Zhang X, Cherukupalli S, De Clercq E, Pannecouque C, Liu X, Zhan P. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 2021 Dec 03;53:116531. doi: 10.1016/j.bmc.2021.116531. Epub 2021 Dec 03. PMID: 34890994.
Copy Download .nbib Format: NLM
Bone deleterious effects of different nrtis in treatment-naïve HIV patients after 12 and 48 weeks of treatment.

Current HIV research

Atencio P, Conesa-Buendía FM, Cabello-Ubeda A, Llamas-Granda P, Pérez-Tanoira R, Prieto-Pérez L, Álvarez BÁ, Acosta IC, Arboiro-Pinel R, Díaz-Curiel M, Largo R, Herrero-Beaumont G, Górgolas M, Mediero A.
PMID: 34353266
Curr HIV Res. 2021 Aug 04; doi: 10.2174/1570162X19666210805094434. Epub 2021 Aug 04.

BACKGROUND: Bone alterations have been observed in the course of HIV infection, characterized by a marked decrease in bone mineral density (BMD) and an increase in the frequency of fractures as a result of fragility. We aim to evaluate...

Cite
Atencio P, Conesa-Buendía FM, Cabello-Ubeda A, et al. Bone deleterious effects of different nrtis in treatment-naïve HIV patients after 12 and 48 weeks of treatment. Curr HIV Res. 2021;doi: 10.2174/1570162X19666210805094434.
Atencio, P., Conesa-Buendía, F. M., Cabello-Ubeda, A., Llamas-Granda, P., Pérez-Tanoira, R., Prieto-Pérez, L., Álvarez, B. �. �., Acosta, I. C., Arboiro-Pinel, R., Díaz-Curiel, M., Largo, R., Herrero-Beaumont, G., Górgolas, M., & Mediero, A. (2021). Bone deleterious effects of different nrtis in treatment-naïve HIV patients after 12 and 48 weeks of treatment. Current HIV research, . https://doi.org/10.2174/1570162X19666210805094434
Atencio, Patricia, et al. "Bone deleterious effects of different nrtis in treatment-naïve HIV patients after 12 and 48 weeks of treatment." Current HIV research vol. (2021). doi: https://doi.org/10.2174/1570162X19666210805094434
Atencio P, Conesa-Buendía FM, Cabello-Ubeda A, Llamas-Granda P, Pérez-Tanoira R, Prieto-Pérez L, Álvarez BÁ, Acosta IC, Arboiro-Pinel R, Díaz-Curiel M, Largo R, Herrero-Beaumont G, Górgolas M, Mediero A. Bone deleterious effects of different nrtis in treatment-naïve HIV patients after 12 and 48 weeks of treatment. Curr HIV Res. 2021 Aug 04; doi: 10.2174/1570162X19666210805094434. Epub 2021 Aug 04. PMID: 34353266.
Copy Download .nbib Format: NLM
Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia.

The American journal of tropical medicine and hygiene

Merati TP, Karyana M, Tjitra E, Kosasih H, Aman AT, Alisjahbana B, Lokida D, Arlinda D, Maldarelli F, Neal A, Arif M, Gasem MH, Lukman N, Sudarmono P, Lau CY, Hadi U, Lisdawati V, Wulan WN, Lane HC, Siddiqui S.
PMID: 34460416
Am J Trop Med Hyg. 2021 Aug 30;105(4):960-965. doi: 10.4269/ajtmh.20-1595.

HIV prevalence in Indonesia is increasing, and only 64% of infected individuals know their status. In a prospective cohort of 1,453 hospitalized patients with unexplained fever, 46 (3.2%) had HIV, including 15 (1.1%) patients without a prior HIV diagnosis....

Cite
Merati TP, Karyana M, Tjitra E, et al. Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia. Am J Trop Med Hyg. 2021;105(4):960-965doi: 10.4269/ajtmh.20-1595.
Merati, T. P., Karyana, M., Tjitra, E., Kosasih, H., Aman, A. T., Alisjahbana, B., Lokida, D., Arlinda, D., Maldarelli, F., Neal, A., Arif, M., Gasem, M. H., Lukman, N., Sudarmono, P., Lau, C. Y., Hadi, U., Lisdawati, V., Wulan, W. N., Lane, H. C., & Siddiqui, S. (2021). Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia. The American journal of tropical medicine and hygiene, 105(4), 960-965. https://doi.org/10.4269/ajtmh.20-1595
Merati, Tuti P, et al. "Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia." The American journal of tropical medicine and hygiene vol. 105,4 (2021): 960-965. doi: https://doi.org/10.4269/ajtmh.20-1595
Merati TP, Karyana M, Tjitra E, Kosasih H, Aman AT, Alisjahbana B, Lokida D, Arlinda D, Maldarelli F, Neal A, Arif M, Gasem MH, Lukman N, Sudarmono P, Lau CY, Hadi U, Lisdawati V, Wulan WN, Lane HC, Siddiqui S. Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia. Am J Trop Med Hyg. 2021 Aug 30;105(4):960-965. doi: 10.4269/ajtmh.20-1595. PMID: 34460416; PMCID: PMC8592138.
Copy Download .nbib Format: NLM
Showing 409 to 416 of 416 entries